Venlafaxine’s therapeutic reference range in the treatment of depression revised: a systematic review and meta-analysis: original investigation
The selective serotonin and norepinephrine reuptake inhibitor venlafaxine is among the most prescribed antidepressant drugs worldwide and, according to guidelines, its dose titration should be guided by drug-level monitoring of its active moiety (AM) which consists of venlafaxine (VEN) plus active m...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
February 2024
|
| In: |
Psychopharmacology
Year: 2024, Volume: 241, Issue: 2, Pages: 275-289 |
| ISSN: | 1432-2072 |
| DOI: | 10.1007/s00213-023-06484-7 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1007/s00213-023-06484-7 Verlag, kostenfrei, Volltext: https://link.springer.com/article/10.1007/s00213-023-06484-7 |
| Author Notes: | X.M. Lense, C. Hiemke, C.S.M. Funk, U. Havemann-Reinecke, G. Hefner, A. Menke, R. Mössner, T.G. Riemer, M. Scherf-Clavel, G. Schoretsanitis, G. Gründer, X.M. Hart |
| Summary: | The selective serotonin and norepinephrine reuptake inhibitor venlafaxine is among the most prescribed antidepressant drugs worldwide and, according to guidelines, its dose titration should be guided by drug-level monitoring of its active moiety (AM) which consists of venlafaxine (VEN) plus active metabolite O-desmethylvenlafaxine (ODV). This indication of therapeutic drug monitoring (TDM), however, assumes a clear concentration/effect relationship for a drug, which for VEN has not been systematically explored yet. |
|---|---|
| Item Description: | Online veröffentlicht: 19. Oktober 2023 Gesehen am 06.03.2024 |
| Physical Description: | Online Resource |
| ISSN: | 1432-2072 |
| DOI: | 10.1007/s00213-023-06484-7 |